Organigram Inc. Business Overview and Financial Insights

Organigram Inc. is a leading Canadian cannabis company that has been around since 2013. The company is headquartered in Moncton, New Brunswick.

They have a strong presence in the Canadian market and have been expanding their operations to meet growing demand. Organigram has a significant share of the Canadian cannabis market.

In terms of financials, Organigram reported net revenue of $125.1 million in the second quarter of 2022. This represents a 35% increase from the same period in 2021.

Their revenue growth is a testament to their ability to adapt to changing market conditions and capitalize on new opportunities.

Suggestion: Fording Canadian Coal Trust

Organigram Inc. has a market capitalization of $226.85M and an enterprise value of $207.04M, indicating a significant presence in the market. Its trailing P/E ratio is 195.72, which is relatively high compared to other companies.

The company's forward P/E ratio is 138.89, suggesting that investors are expecting strong growth in the future. This is reflected in its price/sales ratio of 1.18, which is higher than the industry average.

Here are some key valuation metrics for Organigram Inc.:

In terms of performance, Organigram Inc. has experienced significant growth in recent years, with a 72.97% increase in value over the past six months.

Valuation is a crucial aspect of understanding a company's performance. It helps investors and analysts determine if a company's stock price is fairly valued compared to its earnings and growth potential.

Market capitalization, or market cap, is a key valuation measure that indicates a company's total value. For example, Organigram Global Inc.'s market cap has ranged from $183 million to $21.53 billion over the years.

Enterprise value, on the other hand, takes into account a company's debt and cash, providing a more comprehensive view of its value. In the case of Organigram Global Inc., its enterprise value has fluctuated between $194 million and $21.53 billion.

A company's price-to-earnings (P/E) ratio is another important valuation metric. A higher P/E ratio indicates that investors are willing to pay more for each dollar of earnings. For instance, Organigram Global Inc.'s P/E ratio has been as high as 29.5x.

Here are some valuation measures for different companies:

A company's price-to-sales (P/S) ratio can also be an important valuation metric. For example, Example 1's P/S ratio is 1.18, while Example 3's P/S ratio is 1.33.

In conclusion, valuation is a complex and multifaceted topic that requires careful consideration of various metrics and factors. By examining a company's market cap, enterprise value, P/E ratio, and other valuation measures, investors and analysts can gain a deeper understanding of its performance and potential.

The OGI TO has shown impressive returns in the long term, with a 72.97% increase over the past 6 months. This suggests that investing in OGI TO can be a good option for those looking for a high-growth investment.

One thing to note is that the stock's performance can be quite volatile in the short term. For example, it decreased by 3.76% over the past week.

Here's a breakdown of the OGI TO's performance over different time periods:

It's also worth noting that the OGI TO's trailing total returns as of 2025-10-16 include dividends or other distributions. The benchmark for this is the S&P/TSX Composite index (^GSPTSE).

The OGI TO has maintained a consistent yield over the years, with a current yield of 1.22% and a 5-year average yield of 1.22%. This suggests that investors can expect a relatively stable income stream from this investment.

Organigram Global Inc. has received analyst recommendations that suggest its stock is a good investment opportunity.

Analysts at Alliance Global upgraded their recommendation for Organigram Holdings to Buy from Neutral on April 15, 2024.

This upgrade indicates that analysts believe Organigram's stock has growth potential and is worth considering for investment.

On July 17, 2023, Stifel GMP maintained their Buy recommendation for Organigram Holdings after reviewing its Q2 results and raised their price target to C$4.00.

However, in their previous update on April 13, 2023, Stifel GMP had lowered their price target to C$1.25 due to mixed Q2 results.

Their recommendation was raised to Buy again on January 13, 2023, after Organigram's improved FQ1 results, with the price target kept at C$1.50.

Here is a summary of the analyst recommendations for Organigram Global Inc.:

Organigram Inc.'s financial statements reveal a mixed picture.

The company's profit margin is a relatively modest 3.47%.

Revenue has been steady, reaching $223.82 million in the latest quarter.

Net income available to common shareholders has been $7.77 million in the same period.

Diluted EPS has been a low 0.0100, indicating limited earnings per share.

Here are the key financial metrics:

The company's balance sheet shows a significant amount of cash, with $36.78 million on hand.

Total debt to equity is a relatively manageable 6.68%.

Organigram Inc. has a diverse leadership team.

The company's management team includes Greg Guyatt, the Director of Finance/CFO, who joined in 2024.

Nathalie Kubrick serves as the Chief Operating Officer, though her start date is not specified.

Geoff Riggs is the Chief Tech/Sci/R&D Officer, having taken on the role in 2022.

The company's board of directors consists of three members: Peter Amirault, Dexter John, and Sherry Porter.

Peter Amirault, the Chairman, has been in the role since 2018 and is 64 years old.

Dexter John and Sherry Porter are both directors/board members who joined in 2018, with Dexter being 55 years old and Sherry being 69 years old.

For your interest: Saint John Shipbuilding

Here is a list of the company's leadership team:

Organigram Global Inc. has been making waves in the cannabis industry with its recent press releases. In October, the company launched a new U.S. hemp-derived THC brand called happly, offering targeted formulations for three mood states: socialize, relax, and sleep.

The company has also released a landmark report stating that legal cannabis added $16B to Canada's GDP in 2024. This is a significant milestone for the industry and highlights the economic impact of cannabis legalization.

Organigram Global has also made its earnings call transcript and investor presentation available, providing valuable insights into the company's financial performance and growth strategy.

Here are some key dates to note:

Organigram Global Inc. has been making headlines with its recent press releases. The company launched a new U.S. hemp-derived THC brand called happly, which offers targeted formulations for three mood states: socialize, relax, and sleep.

In September, Organigram Global released a landmark report that found legal cannabis added $16 billion to Canada's GDP in 2024. This is a significant contribution to the country's economy.

On August 13, Organigram Global made available several important documents, including an earnings call transcript, investor presentation, and financial statements. These documents provide valuable insights into the company's financial performance and future plans.

Here are the key press releases from Organigram Global Inc.:

Organigram Inc. is a leading Canadian cannabis company with a strong presence in the industry.

The company was founded in 2009 and went public in 2014, raising $22 million in its initial public offering.

Organigram Inc. operates in the Canadian cannabis market, with a focus on producing high-quality cannabis products for both medical and recreational use.

The company's products are available in various forms, including dried flower, oil, and edibles.

Organigram Inc. has a strong distribution network, with its products available in over 4,000 retail locations across Canada.

The company's revenue has grown significantly over the years, with a 45% increase in revenue in 2020 compared to the previous year.

Organigram Inc. has a strong commitment to research and development, investing in new products and technologies to stay ahead in the market.

Take a look at this: Canadian Breweries